Drugs Made In America Acquisition (DMAAR) Common Equity (2024 - 2025)
Drugs Made In America Acquisition (DMAAR) reported Common Equity of -$7.3 million for Q4 2025, down 2866.77% on a YoY basis from $262544.0 in Q4 2024, and up 0.88% quarter-over-quarter from -$7.3 million in Q3 2025.
Drugs Made In America Acquisition (DMAAR) Common Equity (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition has reported Common Equity for 2 years, with the latest figure at -$7.3 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity fell 2866.77% year-over-year to -$7.3 million; the trailing twelve-month figure through Dec 2025 stood at -$7.3 million (down 2866.77% YoY), and the FY2025 full-year result was -$7.3 million, down 2866.77% from the prior year.
- Common Equity for Q4 2025 stood at -$7.3 million, up from -$7.3 million in the prior quarter.
- The five-year high for Common Equity was -$244845.0 in Q4 2024, with the low at -$7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - | -16.30 Mn |
| 2 | Berto Acquisition | 312.46 Mn | 312.46 Mn | - | -12.19 Mn |
| 3 | Centurion Acquisition | 311.65 Mn | 311.65 Mn | - | -13.79 Mn |
| 4 | GP-Act III Acquisition | 311.36 Mn | 311.36 Mn | - | -14.48 Mn |
| 5 | Churchill Capital Corp IX | 310.79 Mn | 310.79 Mn | - | -11.23 Mn |
| 6 | WEN Acquisition | 309.15 Mn | 309.15 Mn | - | -13.71 Mn |
| 7 | Bold Eagle Acquisition | 275.54 Mn | 275.54 Mn | - | -8.10 Mn |
| 8 | Soulpower Acquisition | 264.91 Mn | 264.91 Mn | - | -11.46 Mn |
| 9 | BTC Development | 262.16 Mn | 262.16 Mn | - | -9.15 Mn |
| 10 | Drugs Made In America Acquisition | - | - | - | -7.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | -7.33 Mn |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.18 Mn |
| Dec 31, 2024 | -244,845.00 |